Last reviewed · How we verify
Tamoxifen, Letrozole, Anastrozole or Exemestane
Tamoxifen, Letrozole, Anastrozole or Exemestane is a Estrogen receptor antagonist (tamoxifen); Aromatase inhibitor (letrozole, anastrozole, exemestane) Small molecule drug developed by Institut Claudius Regaud. It is currently FDA-approved for Hormone receptor-positive breast cancer, adjuvant treatment, Hormone receptor-positive breast cancer, metastatic, Breast cancer prevention in high-risk women (tamoxifen).
These drugs block estrogen signaling in breast cancer cells, either by directly antagonizing the estrogen receptor (tamoxifen) or by inhibiting aromatase to reduce estrogen production (letrozole, anastrozole, exemestane).
These drugs block estrogen signaling in breast cancer cells, either by directly antagonizing the estrogen receptor (tamoxifen) or by inhibiting aromatase to reduce estrogen production (letrozole, anastrozole, exemestane). Used for Hormone receptor-positive breast cancer, adjuvant treatment, Hormone receptor-positive breast cancer, metastatic, Breast cancer prevention in high-risk women (tamoxifen).
At a glance
| Generic name | Tamoxifen, Letrozole, Anastrozole or Exemestane |
|---|---|
| Sponsor | Institut Claudius Regaud |
| Drug class | Estrogen receptor antagonist (tamoxifen); Aromatase inhibitor (letrozole, anastrozole, exemestane) |
| Target | Estrogen receptor alpha (tamoxifen); Aromatase/CYP19A1 (letrozole, anastrozole, exemestane) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Tamoxifen is a selective estrogen receptor modulator that competitively binds to estrogen receptors on hormone-responsive breast cancer cells, blocking estrogen-driven proliferation. Letrozole, anastrozole, and exemestane are aromatase inhibitors that suppress conversion of androgens to estrogen in postmenopausal women, thereby reducing circulating estrogen levels and tumor growth. These mechanisms are effective in estrogen receptor-positive breast cancers.
Approved indications
- Hormone receptor-positive breast cancer, adjuvant treatment
- Hormone receptor-positive breast cancer, metastatic
- Breast cancer prevention in high-risk women (tamoxifen)
Common side effects
- Hot flashes
- Vaginal dryness or discharge
- Arthralgia/myalgia
- Fatigue
- Nausea
- Thromboembolic events (tamoxifen)
- Endometrial cancer (tamoxifen)
- Bone loss/osteoporosis (aromatase inhibitors)
Key clinical trials
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (PHASE3)
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (PHASE3)
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (PHASE3)
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (PHASE2)
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer (PHASE2)
- Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer (PHASE3)
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment (PHASE2)
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tamoxifen, Letrozole, Anastrozole or Exemestane CI brief — competitive landscape report
- Tamoxifen, Letrozole, Anastrozole or Exemestane updates RSS · CI watch RSS
- Institut Claudius Regaud portfolio CI
Frequently asked questions about Tamoxifen, Letrozole, Anastrozole or Exemestane
What is Tamoxifen, Letrozole, Anastrozole or Exemestane?
How does Tamoxifen, Letrozole, Anastrozole or Exemestane work?
What is Tamoxifen, Letrozole, Anastrozole or Exemestane used for?
Who makes Tamoxifen, Letrozole, Anastrozole or Exemestane?
What drug class is Tamoxifen, Letrozole, Anastrozole or Exemestane in?
What development phase is Tamoxifen, Letrozole, Anastrozole or Exemestane in?
What are the side effects of Tamoxifen, Letrozole, Anastrozole or Exemestane?
What does Tamoxifen, Letrozole, Anastrozole or Exemestane target?
Related
- Drug class: All Estrogen receptor antagonist (tamoxifen); Aromatase inhibitor (letrozole, anastrozole, exemestane) drugs
- Target: All drugs targeting Estrogen receptor alpha (tamoxifen); Aromatase/CYP19A1 (letrozole, anastrozole, exemestane)
- Manufacturer: Institut Claudius Regaud — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hormone receptor-positive breast cancer, adjuvant treatment
- Indication: Drugs for Hormone receptor-positive breast cancer, metastatic
- Indication: Drugs for Breast cancer prevention in high-risk women (tamoxifen)
- Compare: Tamoxifen, Letrozole, Anastrozole or Exemestane vs similar drugs
- Pricing: Tamoxifen, Letrozole, Anastrozole or Exemestane cost, discount & access